Formalin-fixed paraffin-embedded (FFPE) prostate specimens are rich sources of molecular pathological information. However, FFPE-based microarray analysis of tissue samples may be hampered by the degradation and chemical alteration of RNA molecules due to the preservation procedure. In this report, we employed a probe analyses of Affymetrix oligonucleotide arrays at individual probe level to compensate for the potential loss of gene identifications associated with compromised mRNA quality in FFPE preparations. Furthermore, to increase the sample quality, we utilized laser capture microdissection of prostate tumor and benign epithelial cells. Remarkably, combination of these approaches recapitulated the common prostate cancer-associated gene expression alteration. Identification of prostate cancer associated-gene expression alterations such as AMACR, Kallikrein gene family and genes associated with androgen signaling such as PDEF and STEAP were consistent with previous findings reported in prostate cancer. These data suggest that combination of laser capture dissection with computational enhancement of microarray data may be useful for the assessment of gene expression changes in FFPE prostate cancer specimens.
Introduction
Over the last century, cellular pathology based on light microscopy has adopted and incorporated new technologies, for example, electron microscopy, immunohistochemistry and molecular biology techniques improving the study of normal and diseased tissues. Almost all clinical and autopsy samples including those from patients with long-term follow-up and from large clinical trials are formalin-fixed and paraffin-embedded (FFPE). In 1988, Rupp and Locker 1 were able to extract RNA successfully from FFPE tissues, but observed the degradation of RNA. Therefore, this type of tissue has been considered to be unsuitable for many genomics and proteomics approaches. However, Reid et al. 2 successfully extracted the RNA of the 1918 'Spanish' influenza virus hemagglutinin gene from our Armed Forces Institute of Pathology (AFIP) archived FFPE specimens of autopsies from patients who succumbed to the 1918 outbreak of the 'Spanish flu. ' Using RNA as starting material, most efforts analyzing global gene expressions have been based on frozen tissues, which usually do not reflect the wide spectrum of histological changes observed in benign, precursor lesions, invasive tumors and their metastases observed in FFPE specimens. Recently, a number of publications stress the usefulness of FFPE specimens for global gene expression analysis. [3] [4] [5] The purpose of this study is to determine the feasibility of FFPE tissues of prostatic carcinoma for 'cell type specific' global gene expression evaluations.
Materials and methods

Study population and processing of specimens
The prostatectomy specimens from six patients with prostate cancer (CaP) treated at Walter Reed Army Medical Center (WRAMC) were processed according to the AFIP protocol. Frozen tissue samples were obtained at the time of prostatectomy. The tissue sampling scheme is shown in Supplementary Figure S1 . In the operating room, the frozen tissue site was marked with India ink to facilitate identification in the whole-mounted paraffinembedded prostatectomy specimens (WMRPS). The frozen tissues were stored in OCT (optimum cutting temperature) compound at À801C. The prostates were fixed in 10% neutral-buffered formalin for at least 72 h before sectioning at 2.25-2.3 mm intervals and totally embedded in low melting paraffin as whole mounts. Hematoxylin and eosin-stained sections of 4 mm thickness were used for histopathological analysis. Each separate tumor was graded according to the Gleason grading system and the WHO/Mostofi grading system for nuclear grade and glandular differentiation, and staged according to the TNM (Tumor, Node, Metastasis) system. [6] [7] [8] In the whole mounts, the frozen section sites could be identified based on the presence of India ink.
Of 18 patients utilized for microarray analysis of frozen samples, 9 six were randomly selected for this study. The year of surgery, grade and stage of the tumors are shown in Supplementary Table S1. Hematoxylin and eosin sections of the frozen sample and the corresponding prostatectomy section were reviewed to optimize the comparison between frozen and paraffin samples for future studies.
Laser capture microdissection
The PixCell II Laser Capture Microdissection System (Arcturus, Mountain View, CA, USA) was used to microdissect prostate epithelial cells from FFPE tissue sections. For each specimen, approximately 2000 shots were used to obtain approximately 5000-6000 cells as described earlier. 9 One shot generally captured 2-3 cells. The power (range 25-100 mW) and pulse duration (range 550 ms-6.0 ms) of the laser were adjusted in each specimen as necessary to allow complete tissue capture using the 7.5 to 30-mm spot size laser beam. Optimal quality of the cell samples was defined by the pathologist's eye as less than 10% contamination with stromal tissue.
The cap containing the captured tissue was placed in a microtube and prepared for further processing.
RNA extraction and T7 based linear RNA amplification
Total RNA was isolated from the laser capture microdissection samples with the Paradise MicroRNA kit (Arcturus, Mountain View, CA, USA), quantified using RiboGreen dye (Molecular Probes, Eugene, OR, USA) and VersaFluor fluorimeter (Bio-Rad, Hercules, CA, USA). Linear RNA amplification was performed using Paradise RNA amplification kit (Arcturus). Two nanograms of total RNA from laser capture microdissection-derived epithelial cells of normal as well as tumor tissue from each patient was used for the first round of amplification. During the second round of amplification after cDNA synthesis and purification, the samples were biotinylated during in vitro transcription, and used for the GeneChip analysis.
Gene chip experiments
Linearly amplified aRNA was used to hybridize to highdensity oligonucleotide human genome set, GeneChip HG X3P array (Affymetrix, Santa Clara, CA, USA) that contains 61 359 probe sets which represent approximately 54 000 transcripts. For microarray analysis, FFPE samples encounter unique challenges, including chemical modification and potential fragmentation of RNA molecules. To overcome these potential challenges, Affymetrix and Arcturus developed the HG X3P array designed to focus on sequences located closer to the 3' end of the transcripts compared with standard GeneChip arrays. Isolated RNA was amplified using the Paradise RNA amplification kit (Arcturus). Biotinylated aRNA targets were prepared using the MEGA Script T7 in vitro Transcription kit (Ambion, Austin, TX, USA). The biotinlabeled cRNA was purified using the Qiagen RNeasy spin columns (Qiagen, Valencia, CA, USA) following the manufacturer's protocol. The biotin-labeled cRNA was fragmented in a 40ml reaction mixture containing 40 mM Tris-acetate, pH 8.1, 100 mM potassium acetate and 30 mM magnesium acetate incubated at 941C for 35 min and then put on ice. The biotin labeled and fragmented aRNA was hybridized to the HG X3P GeneChip array (Affymetrix). Hybridization and scanning procedures were essentially same as described before. 9 
Image analysis and data collection
Intensity values for probes were captured from the GeneChip images using the GCOS (GeneChip Operating System). Affymetrix GeneChip Microarray Analysis Software version 3. 
Data analysis
The expression data from the six CaP patients (24 GeneChips) were analyzed by Genomatix ChipInspector and the pathway edition of Bibliosphere as described by the vendor (Genomatix GmbH, Munich, Germany, http://www.genomatix. de).
Results
The RNA preparations from six FFPE-WMRPS yielded similar expression profiles in two consecutive GeneChip experiments (FFPE1 and FFPE2). Correlation coefficients (r) were calculated using Pearson's correlation (FFPE1 and FFPE2; average FFPE1 and FFPE2 tumor samples, r ¼ 0.927025; average FFPE1 and FFPE2 benign samples, r ¼ 0.930214). To determine expression differences between tumor and benign epithelial cells of six WMRPS, GeneChip CEL files were analyzed by ChipInspector software (http://www.genomatix.de), which evaluates GeneChip data at a single probe level. ChipInspectordefined CaP-associated genes were further analyzed by BiblioSphere software (http://www.genomatix.de.), which incorporates published literature and mesh filters for disease and anatomy (Supplementary Figure S2 and  S3) . 10 This analysis revealed most of the genes that are reported to be frequently altered in CaP. Of note, in this study, there was consistent upregulation of AMACR that Transcriptome analyses of benign and malignant prostate epithelial cells B Furusato et al is already used in surgical pathology. 11, 12 Other CaPassociated gene expression alterations included SPON2, STEAP2, OR51E2 (PSGR), SPDEF.
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Overall, there was high degree of reproducibility between two independent GeneChip experiments (Table 1 and Figure 1 ).
Discussion
Our study is in agreement with Tomlins et al., 17 who have recently reported promising global gene expression data from FFPE CaP specimens.
CaP is known for its multifocality and heterogeneity. On the basis of this study, FFPE CaP specimens can be utilized effectively for global gene expression strategies. Two independent global gene expression analyses starting from RNAs of laser capture microdissectionderived benign and malignant epithelial cells from six FFPE-WMRPS revealed prostate tumor cell-specific gene expression alterations that have been consistently highlighted in previous evaluations of CaP global gene 
Abbreviation: FFPE, formalin-fixed and paraffin-embedded. '+', genes present in FFPE1 data or in FFPE2 data from Bibliosphere analysis or in both and 'À', genes absent in either FFPE1 data or in FFPE2 data from Bibliosphere analysis. Figure 1 Prostate cancer-associated genes defined by ChipInspector and Bibliosphere. Tumor vs benign ratio of 2108 genes from ChipInspector analysis of FFPE1 data and 2180 genes from FFPE2 data (using natural logarithm of normalized expression signal ratios from GeneChip CEL files) were used as input data. Genes from FFPE1 data were labeled with small black boxes and small white box labels indicate genes from FFPE2 data. This network was constructed on 28 genes remaining after filter 'disease' using MeSH category 'prostatic neoplasm' and filter 'tissue' using MeSH category 'prostate' was applied. Co-citation level was restricted to input genes (IN). Input genes are all genes that were significantly regulated in the experiments: connection lines were drawn as a result of co-citation of two genes within one sentence. Green or partially green connection lines indicate transcription factor (TF) binding site match in target promoter of the gene connected by this line. ST indicates the gene product is part of a Genomatix signal-transduction pathway. Color coding: red color indicates genes upregulated in tumor in comparison to benign, and blue color indicates genes downregulated in tumor in comparison to benign. FFPE, formalin-fixed and paraffin-embedded.
Transcriptome analyses of benign and malignant prostate epithelial cells B Furusato et al expression using frozen tissues from our and other laboratories. 9, 11, 12 Despite the small sample size and limited number of cells analyzed per specimen benign and malignant cells were reproducibly discriminated by tumor cell-associated genes expression profile.
Moreover, as demonstrated in Figure 1 , the highly upregulated genes noted in both studies are part of the same gene network as evident from the BiblioSphere cocitation analysis. It is also remarkable that genes that were found in only one of the FFPE groups were often part of the same network supporting the view that the two experiments highlighted slightly different details of essentially the same overall picture.
This study underscores the potential of developing cell type-specific gene expression/pathway signatures from archival FFPE-WMRPS tissues that may provide a host of new biomarkers and therapeutic targets associated with disease progression and aggressive forms of CaP. Future studies are warranted to establish the value and limitations of FFPE CaP tissues in defining clinically relevant biomarkers using tissues from patients in whom the clinical progression features or therapeutic outcome is already known.
